Table 4. Pharmacokinetics of 99mTc-P60+CRB NBG (orally and Ivag) and 99mTc-CRB aqueous form (Ivag) at Different Time Intervals in Sprague Dawley Rats.
| Formulation and route of administration | ORGAN | Cmax (%/gm) | Tmax (hr) | AUC 0-24 hr |
| Oral 99mTc-P60+CRB NBG | BLOOD | 2.26 | 6 | 31.925 |
| KIDNEY | 2.01 | 6 | 33.22 | |
| URINARY BLADDER | 1.08 | 6 | 18.6 | |
| SPLEEN | 1.20 | 6 | 22.62 | |
| Ivag99mTc-P60+CRB NBG | BLOOD | 2.52 | 6 | 40.26 |
| KIDNEY | 3.20* | 3 | 68.27* | |
| URINARY BLADDER | 3.64* | 3 | 59.30* | |
| SPLEEN | 1.58 | 6 | 28.19 | |
| Ivag99mTc P60+CRB Aqueous form | BLOOD | 0.97 | 3 | 14.92 |
| KIDNEY | 1.21 | 3 | 20.955 | |
| URINARY BLADDER | 2.30 | 0.5 | 23.52 | |
| SPLEEN | 0.68 | 3 | 11.64 |
Only statistically significant outcomes at p<0.05 have been reported with *. AUC: area under the curve, CRB: Cranberry, P60: Polyphenon 60, Ivag: intravaginal, NBG: Nanoemulsion based gel.*The Cmax and AUC of radiolabelled NBG administered via intravaginal route in kidney and urinary bladder showed significant difference as compared to other groups of study.